CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 19 enrolled
Drug / intervention
Ketamine +1 moredrug
Likely dose
Ketamine 0.25mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01089361
NCT01089361Phase 2Completed
CompareCT.gov

Immunomodulatory Properties of Ketamine in Sepsis

Beth Israel Deaconess Medical Center·interventional·Posted Mar 18, 2010·Updated Aug 21, 2017

In Brief

A Phase 2 clinical trial evaluating Ketamine and Normal Saline placebo for Sepsis. Completed, enrolled 19 participants across 1 site.

Detailed Summary

The aim of the study is to assess the effect of short-term infusion of ketamine at analgesic dosage on the immune response, morbidity and mortality among patients suffering from septic shock. We hypothesize that ketamine will modulate the cytokine response to sepsis and reduce morbidity and mortality.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSepsis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 18, 2010
Enrollment StartDec 1, 2009
Primary CompletionJun 1, 2010
Study CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 16.3 years ago

Interventions

Ketaminedrug

The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.

Normal Saline placebodrug

The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.